Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab | Zendy

Tjensvoll Anne Bolette | Zendy; Lauvsnes Maria Boge | Zendy; Norheim Katrine Brekke | Zendy; Omdal Roald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab

Author(s) -

Tjensvoll Anne Bolette,

Lauvsnes Maria Boge,

Norheim Katrine Brekke,

Omdal Roald

Publication year - 2019

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.1987

Subject(s) - medicine , triptans , rituximab , intrathecal , pathogenesis , primary headache , immunology , migraine , anesthesia , antibody

Key Clinical Message A severe and persistent migrainous headache in a patient with primary Sjøgren's syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opioids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituximab. We hypothesize that brain‐resident autoreactive B cells were involved in headache pathogenesis and were eliminated by this procedure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research